Novartis has stopped development of its Aurograb treatment for bacterial infections after it showed a lack of efficacy in mid-stage trials, and said it would take a $235 million impairment charge.
Novartis acquired Aurograb, which was being assessed for treating methicillin-resistant staphylococcus aureus (MRSA), in 2006 when it bought NeuTec Pharma, a specialist in fighting hospital superbugs, for nearly $570 million.
More
No comments:
Post a Comment